present
fda
approv
chlorin
contain
drug
avail
market
mani
pharmaceut
import
drug
candid
preclin
trial
thu
quit
obviou
expect
come
decad
even
greater
number
new
chlorinecontain
pharmaceut
market
chlorin
compound
repres
famili
compound
promis
use
medicin
chemistri
review
describ
recent
advanc
synthesi
chlorin
contain
heterocycl
compound
divers
biolog
agent
drug
pharmaceut
industri
inspir
discoveri
develop
potent
effect
chlorin
drug
numer
deathcaus
diseas
chlorin
one
vital
industri
chemic
util
variou
endus
industri
tremend
sprite
pharmaceut
major
key
ingredi
drug
treat
mani
diseas
mening
cholera
plagu
typhoid
bacteri
skin
infect
respiratori
nervou
system
problem
etc
per
busi
wire
berkshir
hathaway
compani
report
therapeut
percentag
sale
present
address
import
chlorin
chemistri
pharmaceut
drug
report
appli
econom
canada
tabl
unit
state
pharmaceut
depend
chlorin
chemistri
includ
drug
use
treatment
stomach
ulcer
cancer
anemia
high
cholesterol
depress
epilepsi
per
statist
benefit
chlorin
chemistri
estim
billion
per
year
net
gain
pharmaceut
us
canada
use
chlorin
high
billion
per
year
health
care
system
report
appli
econom
canada
accord
busi
wire
berkshir
hathaway
compani
report
estim
chlorin
market
period
approxim
drug
present
chemic
structur
contain
chlorin
number
group
differ
one
studi
detail
compound
among
approv
drug
nearli
contain
singl
chlorin
atom
possess
two
chlorin
possess
three
chlorin
atom
possess
four
chlorin
possess
six
chlorin
compound
surprisingli
none
drug
approv
five
chlorin
atom
yet
also
among
monosubstitut
ccl
four
disubstitut
ccl
none
approv
drug
trisubstitut
ccl
group
interest
research
gap
suggest
chlorin
continu
industri
ruler
role
provid
benefit
consum
pharmaceut
futur
improv
qualiti
advantag
chlorin
chemistri
scientist
need
advanc
understand
chlorin
view
medicin
chemistri
futur
see
tabl
presenc
chlorin
atom
play
pivot
role
number
natur
product
antibiot
clindamycin
vancomycin
chloramphenicol
griseofulvin
cours
time
found
empir
introduct
chlorin
atom
one
specif
posit
biolog
activ
molecul
may
substanti
improv
intrins
biolog
activ
properti
carbonchlorin
bond
ccl
organochlorin
analys
henschler
howev
lowmolecularweight
chemic
investig
analysi
electrophil
reactiv
carbon
centr
adjac
chlorin
atom
facilit
displac
chlorin
bio
nucleophil
determin
observ
biolog
properti
increas
lipophil
whole
molecul
chlorin
substitu
lead
higher
partit
chlorin
compound
lipophil
phase
cell
membran
lipophil
domain
protein
caus
higher
local
concentr
compound
near
biolog
target
site
necessarili
higher
biolog
activ
import
effect
nonreact
chlorin
atom
biolog
activ
mani
compound
come
chlorin
substitu
aromat
heteroaromat
olefin
moieti
properti
mention
give
rise
steric
andor
electron
effect
chlorin
substitu
lead
local
electron
attract
repuls
steric
interfer
amino
acid
residu
surround
posit
chlorin
atom
bind
pocket
protein
turn
may
caus
tighter
interact
loosen
contact
amino
acid
close
chlorin
part
activ
molecul
either
one
may
affect
function
target
protein
caus
increas
decreas
biolog
activ
case
howev
chlorin
substitu
may
specif
effect
primari
biolog
properti
molecul
attach
chlorin
compound
necessarili
toxic
danger
highli
reactiv
chemic
polychlorin
compound
compar
regard
toxicolog
properti
unreact
compound
low
degre
chlorin
chlorin
atom
one
mani
possibl
substitu
use
synthet
organ
chemistri
remain
futur
one
import
tool
probe
structureact
relationship
life
scienc
research
molecular
compon
commerci
compound
order
provid
safer
select
environment
compat
product
higher
activ
medicin
agricultur
applic
chlorin
medicin
chemistri
one
fastest
grow
hot
area
chemistri
fascin
instruct
role
halogen
distribut
field
drug
develop
surprisingli
among
four
halogen
chlorin
cl
one
frequent
found
drug
other
even
fluorin
f
interestingli
drug
element
sulphur
chlorin
fluorin
place
respect
c
h
n
remain
phosphor
p
bromin
br
iodin
rest
top
element
approv
drug
remark
cl
f
heavi
hitter
cl
f
br
problem
antibiot
resist
among
pathogen
bacteria
old
antibiot
antibiot
resist
acceler
use
misus
antimicrobi
drug
major
univers
challeng
public
health
remark
increas
human
pathogen
bacteria
observ
past
decad
due
resist
one
antibiot
number
infect
caus
resist
organ
succeed
respond
convent
treatment
even
last
choic
antibiot
also
lost
power
loss
effect
resist
power
old
antibiot
new
upcom
bacteri
pathogen
prompt
us
develop
novel
less
toxic
highli
effect
antimicrobi
agent
divers
structur
tabl
chlorin
base
drug
categori
diseas
total
categori
tabl
list
fda
approv
chlorin
contain
drug
market
fight
emerg
antibioticresist
bacteri
infect
review
articl
focus
chlorin
contain
analogu
core
substitu
antibacteri
agent
drug
develop
mujumdar
cowork
synthes
novel
class
sulfamatecontain
natur
product
screen
vitro
antibacteri
properti
titl
compound
synthes
accord
literatur
report
shown
scheme
commerci
avail
react
tosyl
acid
optim
reaction
condit
afford
protect
adenosin
precursor
react
chlorosulfonyl
amin
presenc
dbu
base
obtain
correspond
adenosin
moder
good
yield
protect
group
compound
remov
use
mixtur
solut
tfa
water
vv
afford
target
compound
vitro
antimicrobi
activ
evalu
show
compound
possess
highest
antibacteri
activ
mic
mm
e
coli
structureact
relationship
sar
reveal
presenc
chlorin
atom
highli
enhanc
antibacteri
properti
compound
addit
presenc
sulfonamid
group
also
favour
increas
antibacteri
activ
potent
compound
compound
lead
compound
need
design
synthes
investig
wang
cowork
develop
chlorin
contain
thiochrom
deriv
screen
vitro
antimicrobi
activ
substitut
thiophenol
react
koh
ethanol
presenc
water
c
yield
compound
compound
react
bchloropropion
acid
cycliz
presenc
concentr
h
afford
via
intramolecular
friedelcraft
reaction
later
compound
treat
vilsmeierhaack
condit
produc
key
intermedi
compound
react
variou
substitut
amin
treat
nabh
oac
room
temperatur
yield
final
target
compound
scheme
synthes
compound
test
vitro
antifung
activ
differ
fungal
strain
base
vitro
antimicrobi
result
two
compound
show
excel
antifung
activ
c
albican
mic
mgml
c
neoforman
mic
mgml
respect
karthikeyan
et
al
synthes
novel
chlorin
contain
potent
antimicrobi
compound
begin
start
materi
react
variou
substitut
aldehyd
presenc
ethanol
aq
koh
reflux
condit
yield
good
yield
compound
underw
bromin
chloroform
give
bromo
substitut
compound
chalcon
dibromid
treat
aryloxi
acid
hydrazid
presenc
triethylamin
absolut
ethanol
furnish
pyrazolin
scheme
good
yield
compound
zone
inhibit
mm
p
aeruginosa
zone
inhibit
mm
p
aeruginosa
turn
potent
antibacteri
agent
compound
zone
inhibit
mm
fumigatu
zone
inhibit
mm
p
marneffei
turn
potent
antifung
agent
recent
zha
cowork
synthes
benzo
thiazolehydrazon
test
vitro
antimicrobi
activ
synthet
rout
depict
scheme
b
intermedi
synthes
accord
literatur
report
method
presenc
catalyt
amount
glacial
acet
acid
deriv
obtain
good
excel
yield
obtain
deriv
evalu
vitro
antimicrobi
activ
variou
bacteri
fungal
pathogen
compound
found
potent
antifung
agent
mm
inhibit
zone
mgml
niger
structureact
relationship
sar
reveal
presenc
electron
withdraw
group
ewg
cl
br
f
phenyl
ring
increas
antifung
properti
presenc
electron
donat
group
edg
oh
och
diminish
antifung
properti
compound
may
serv
new
potenti
antibacteri
candid
futur
recent
goa
et
al
develop
potent
antimicrobi
aminothiazolyl
berberin
deriv
illustr
sb
scheme
b
initi
compound
react
hydrazinecarbothioamid
presenc
glacial
acet
acid
ethanol
optim
reaction
condit
afford
compound
moder
good
yield
subsequ
compound
react
yield
final
compound
convert
aminothiazolyl
berberin
deriv
use
substitut
benzyl
chlorid
optim
reaction
condit
among
synthes
deriv
compound
show
excel
antibacteri
activ
mic
valu
mmolml
gramneg
baumanii
sar
reveal
introduct
chlorin
atom
significantli
improv
antibacteri
effect
ewg
cl
use
improv
antibacteri
activ
molecular
dock
show
hydrogen
bond
exist
supramolecular
interact
dna
gyras
activ
molecul
fig
synthesi
novel
class
antimicrobi
quinolin
bear
benzimidazol
hybrid
carri
garudachari
et
al
target
final
compound
synthes
two
step
first
step
isatin
react
amethylketon
aqueou
ethanol
yield
good
yield
second
step
react
variou
polyphosphor
acid
media
afford
quinolin
incorpor
benzimidazol
deriv
scheme
compound
found
potent
antibacteri
agent
aureu
mm
inhibit
zone
compound
found
potent
aureu
mm
inhibit
zone
sar
result
reveal
presenc
fuse
pyridin
ring
benzimidazol
moieti
well
group
second
posit
quinolin
ring
relationship
antibacteri
activ
presenc
two
chlorin
atom
benzimidazol
ring
along
group
second
posit
quinolin
ring
account
enhanc
activ
compound
karthikeyan
et
al
synthes
new
seri
triazol
substitut
compound
act
potent
antimicrobi
agent
start
materi
react
substitut
phenacyl
bromid
presenc
base
optim
reaction
condit
yield
substitut
phenyl
ethanon
underw
cycliz
presenc
ppa
obtain
seri
contain
thiazolotriazol
good
yield
scheme
compound
triazol
chloro
substitu
found
activ
antibacteri
agent
mm
inhibit
zone
p
aeruginosa
antifung
agent
mm
inhibit
zone
niger
among
synthes
seri
develop
area
anticanc
therapeut
agent
one
key
challeng
medicin
chemistri
cancer
univers
name
group
diseas
character
uncontrol
cell
prolifer
found
world
cancer
second
major
caus
death
worldwid
year
alon
estim
american
die
cancer
refer
death
per
day
accord
assess
world
health
organ
global
cancer
rate
could
increas
year
approxim
million
cancer
lung
bronchu
prostat
colorect
continu
common
caus
cancer
death
cancer
consist
group
cell
origin
singl
cell
uncontrol
growth
rapid
prolifer
properti
present
wide
rang
cytotox
drug
either
alon
combin
use
treat
cancer
sever
drug
differ
phase
clinic
trial
cytotox
drug
suffer
sever
drawback
abl
differenti
cancer
normal
cell
type
consequ
caus
seriou
side
effect
often
cumul
doselimit
anticanc
drug
recent
clinic
trial
exhibit
unnecessari
organ
toxic
lack
cell
specif
short
circul
halflif
notic
tendenc
induc
resist
target
cell
henc
order
save
live
million
peopl
global
continu
effort
made
develop
effect
anticanc
drug
candid
minim
side
effect
less
cost
amin
triethyl
amin
yield
amino
propaneol
accord
previou
report
method
compound
react
sulfonyl
chlorid
presenc
base
optim
reaction
condit
yield
mesyl
high
yield
intermedi
treat
variou
substitut
amino
compon
util
sodium
hydrid
base
afford
final
nalkyl
deriv
moder
good
yield
synthes
compound
evalu
vitro
antibreast
cancer
activ
among
compound
found
potent
analogu
test
two
cancer
cell
line
gi
mm
gi
mm
bio
assay
result
suggest
compound
analogu
could
serv
potent
anticanc
agent
develop
new
group
effect
cancer
chemotherapeut
baijiao
et
al
report
simpl
protocol
synthesi
quinolin
contain
hybrid
evalu
vitro
anticanc
activ
differ
cancer
cell
line
initi
start
materi
dichloroquinazolin
react
substitut
selenium
contain
analogu
presenc
hydrogen
chlorid
isopropanol
afford
target
compound
good
yield
scheme
among
compound
found
potent
anticanc
agent
test
cell
line
ic
valu
rang
nm
zolnowska
cowork
report
welldesign
synthet
approach
toward
synthesi
function
guanidin
contain
deriv
screen
anticanc
activ
synthet
rout
outlin
scheme
initi
intermedi
compound
guanidin
deriv
synthes
reaction
appropri
aminoguanidin
presenc
triethylamin
optim
reaction
condit
intermedi
treat
variou
substitut
amin
presenc
dipea
base
argon
atmospher
reflux
condit
h
yield
correspond
guanidin
substitut
hybrid
good
moder
yield
compound
display
excel
inhibitori
potenc
hca
ix
ki
valu
nm
show
promin
cytotox
effect
ic
mm
hela
cancer
cell
line
sar
repres
presenc
two
chlorin
scheme
synthet
rout
pyrazolopyrimidin
deriv
potent
anticanc
agent
reagent
condit
nh
nh
meoh
c
h
ii
hcl
ch
cl
c
h
iii
tea
ch
cl
c
h
scheme
synthet
rout
chlorin
contain
drug
potent
anticanc
agent
reagent
condit
tea
anhydr
thf
h
c
h
rt
ii
xnh
dipea
c
argon
atmospher
h
electronwithdraw
group
aromat
ring
highli
enhanc
anticanc
activ
hand
presenc
sulfonyl
sulfonamid
group
also
increas
anticanc
activ
compound
pogorzelska
et
al
evalu
synthes
compound
anticanc
activ
found
effect
compound
synthes
new
seri
target
compound
show
scheme
start
materi
react
phenylpropiolaldehyd
diethyl
acet
presenc
ptsa
ethanol
reflux
condit
yield
guanidin
moder
good
yield
synthes
compound
underw
cui
mediat
electrophil
cycliz
balkyn
hydrazon
unfortun
step
provid
desir
deriv
led
copper
complex
pyrazol
moieti
anoth
way
treatment
compound
ptsa
optim
reaction
condit
afford
final
compound
magar
cowork
synthes
seri
novel
benzofuran
substitut
hybrid
screen
vitro
antiprolif
activ
usual
target
compound
synthes
three
simpl
step
first
step
three
differ
chlorinesubstitut
pyridinium
iodid
salt
synthes
good
yield
heat
correspond
aryl
methyl
keton
presenc
iodin
pyridin
c
h
second
step
al
catalyz
condens
reaction
appli
prepar
six
aryl
one
condens
one
aryl
aldehyd
methylen
chlorid
h
room
temperatur
final
modifi
ohnk
pyridin
synthet
method
use
synthes
target
compound
mixtur
aryl
one
pyridinium
iodid
salt
nh
oac
glacial
acet
acid
heat
c
h
afford
compound
scheme
consider
yield
synthes
compound
evalu
vitro
topoisomeras
ii
inhibit
antiprolif
activ
compound
exhibit
potent
antiprolif
activ
posit
control
etoposid
ic
mm
ic
mm
cell
line
sar
result
suggest
chlorin
compound
show
better
antiprolif
activ
correspond
nonchlorin
compound
chlorin
ring
import
inhibit
topo
ii
activ
result
provid
use
inform
develop
benzofuro
pyridin
deriv
novel
class
topoisomerasetarget
anticanc
agent
synthesi
new
class
antiprolif
agent
carri
yao
et
al
synthet
rout
lengthi
includ
five
step
start
acid
scheme
compound
react
socl
reflux
condit
c
h
produc
chlorid
follow
addit
scheme
potent
anticanc
agent
reagent
condit
phenylpropiolaldehyd
diethyl
acet
eq
eq
ptsa
eq
synthet
rout
chlorin
contain
chalcon
analogu
potent
antileishmani
activ
reagent
condit
acrolein
k
co
reflux
ii
appropri
acetophenon
naoh
etoh
iii
methyl
vinyl
keton
k
co
reflux
iv
appropri
aldehyd
naoh
etoh
methanol
room
temperatur
h
gener
methyl
consequ
compound
react
variou
substitut
amin
presenc
ch
ohthf
c
h
yield
treat
provid
correspond
diaromat
ether
consider
yield
final
compound
treat
substitut
diaromat
ether
dcm
afford
final
target
thiourea
deriv
consider
yield
scheme
newli
synthes
compound
evalu
vitro
antiprolif
activ
cell
line
compound
found
potent
antiprolif
agent
ic
valu
mm
cell
line
zhao
et
al
perform
synthesi
antiprolif
compound
test
activ
four
human
cancer
cell
line
intermedi
prepar
follow
earlier
report
procedur
prepar
intermedi
treat
ethyl
glyoxal
etoh
reflux
condit
h
led
propylthio
moder
yield
intermedi
hydrolyz
carboxyl
acohh
yield
final
compound
coupl
variou
substitut
amin
use
coupl
reagent
edcihobt
dichloromethan
room
temperatur
afford
final
target
compound
scheme
compound
show
excel
antiprolif
activ
ic
valu
mm
mm
respect
sar
reveal
presenc
piperazin
group
highli
enhanc
antiprolif
activ
suggest
piperazin
substitut
play
import
role
enhanc
antiprolif
activ
compound
methyl
substitut
piperazin
group
found
potent
antiprolif
agent
seri
luo
cowork
develop
seri
novel
chlorin
contain
compound
enhanc
vitro
antitumour
activ
initi
commerci
avail
acid
condens
formamid
c
react
k
co
acetonitril
c
h
yield
intermedi
compound
react
substitut
aldehyd
presenc
anhydr
alcohol
aceton
room
temperatur
provid
final
target
compound
good
yield
scheme
compound
found
potent
antitumor
agent
ic
valu
mm
mm
cell
line
compound
could
consid
use
templat
futur
develop
potent
antitumor
agent
inflamm
demot
localis
physic
condit
caus
swell
red
heat
pain
mediat
releas
proinflammatori
mediat
like
bradykinin
cytosin
increas
prostaglandin
synthesi
rate
nonsteroid
antiinflammatori
drug
nsaid
exist
two
isomer
form
name
constitut
form
induc
form
inhibit
cyclooxygenas
cox
inhibit
biosynthesi
prostaglandin
pg
role
enzym
maintain
gastric
integr
kidney
function
wherea
may
caus
inflamm
pain
shantharam
cowork
develop
new
seri
imidazol
hydrazon
potent
antiinflammatori
agent
synthesi
imidazol
base
hydrazon
wer
perform
manner
outlin
scheme
start
materi
acid
convert
ethylest
use
tmscl
ethanol
room
temperatur
follow
addit
excess
hydrazin
hydrat
afford
correspond
imidazol
hydrazid
compound
treat
variou
substitut
aldehyd
ethanol
c
h
yield
final
imidazolehydrazon
good
yield
compound
found
potent
antiinflammatori
agent
ic
valu
mm
sar
reveal
presenc
electron
withdraw
cl
group
phenyl
ring
highli
enhanc
antiinflammatori
activ
continu
interest
drug
develop
program
research
group
rakesh
identifi
novel
quinazolinonehydrazon
potent
vitro
antiinflammatori
activ
quinazolinon
start
materi
methyl
use
tmscl
methanol
room
temperatur
follow
addit
excess
hydrazin
hydrat
afford
correspond
quinazolinon
hydrazid
quinazolinonehydrazon
obtain
reaction
differ
aromat
aldehyd
presenc
catalyt
amount
glacial
acet
acid
scheme
compound
ic
mmml
ic
mmml
show
excel
antiinflammatori
activ
lower
ic
valu
standard
compound
aspirin
ic
mm
ml
sar
reveal
presenc
electron
withdraw
cl
group
phenyl
ring
highli
enhanc
antiinflammatori
activ
length
quinozolinon
alkyl
chain
also
play
major
role
increas
activ
presenc
edg
oh
ome
phenyl
ring
diminish
antiinflammatori
activ
cyclocondens
compound
substitut
aldehyd
presenc
catalyt
amount
sodium
acet
acet
anhydrid
optim
reaction
condit
yield
good
yield
compound
treat
sulfanilamid
glacial
acet
acid
afford
compound
good
yield
scheme
among
synthes
compound
compound
found
excel
antiinflammatori
activ
ic
mm
ic
mm
potent
standard
celecoxib
seri
abdelrahman
colleagu
report
set
thirteen
deriv
pchloroanilin
firstli
condens
pchloroanilin
diethyl
oxalpropion
afford
correspond
imin
cycliz
polyphosphor
acid
yield
acid
ethyl
ester
excel
yield
hydrolyz
carboxyl
acid
basic
condit
coupl
substitut
amin
use
bop
presenc
dipea
yield
scheme
develop
hybrid
evalu
vitro
antiinflammatori
activ
compound
ic
mm
ic
mm
ic
mm
ic
mm
show
excel
antiinflammatori
activ
compar
refer
drug
celecoxib
dock
studi
explain
result
obtain
vitro
cox
assay
base
structur
featur
bind
pattern
insid
activ
site
obvious
two
activ
hit
adopt
similar
bind
pattern
interact
cocrystal
bromocelecoxib
ligand
benzimidazol
phenyl
piperazin
moieti
respect
assum
posit
sulfonamid
moieti
within
addit
side
pocket
fig
new
seri
eighteen
benzo
imidazolehydrazon
synthes
kumar
et
al
use
commerci
avail
compound
start
materi
compound
esterifi
use
con
h
ethanol
reflux
condit
obtain
compound
good
yield
subsequ
compound
treat
propylamin
tea
afford
compound
compound
prepar
nitro
reduct
cycliz
use
sodium
dithionit
dmso
solvent
c
onepot
reaction
produc
compound
within
h
excel
yield
ester
group
treat
hydrazin
hydrat
ethanol
medium
reflux
condit
h
provid
hydrazid
final
target
hydrazon
obtain
condens
variou
substitut
aldehyd
ethanol
catalyt
amount
glacial
acet
acid
scheme
prepar
analogu
screen
vitro
antiinflammatori
activ
compound
show
excel
antiinflammatori
activ
inhibit
compar
refer
drug
indomethacin
inhibit
sar
result
reveal
presenc
ewd
cl
br
phenyl
ring
increas
antiinflammatori
activ
presenc
edg
oh
och
phenyl
ring
reduc
antiinflammatori
activ
tuberculosi
highli
infecti
chronic
deadli
diseas
caus
mycobacterium
tuberculosi
mtb
diseas
threaten
human
life
affect
lung
primarili
pulmonari
tb
distant
vital
organ
drugresist
tb
drtb
multidrugresist
tb
mdrtb
extens
drugresist
tb
xdrtb
total
drug
resist
tb
tdr
emerg
nowaday
complet
resist
action
present
avail
standard
drug
infect
tb
common
caus
around
million
death
million
clinic
case
globe
report
howev
treatment
tb
drug
isoniazid
inh
ethambutol
rifampicin
rif
pyrazinamid
pza
prove
highli
effect
diabet
one
insist
diseas
rise
world
accord
estim
data
obtain
around
million
peopl
suffer
diabet
world
may
increas
million
blood
glucos
chang
due
insulin
resist
regard
featur
diabet
case
give
rais
sever
problem
like
high
blood
pressur
heart
problem
kidney
failur
stroke
blind
consequ
inhibit
aglucosidas
ec
key
carbohydr
hydrolyz
enzym
could
serv
effect
methodolog
prevent
treat
diabet
control
postprandi
glucos
level
suppress
postprandi
hyperglycemia
aglucosidas
specif
perform
hydrolysi
aglucopyranosid
bond
result
product
dglucos
nonreduc
end
sugar
sever
aglucosidas
inhibitor
like
acarbos
voglibos
miglitol
appear
clinic
treatment
type
ii
diabet
mellitu
howev
number
intens
side
effect
call
develop
potent
structur
divers
safe
efficaci
drug
effect
treatment
diabet
mellitu
aglucosidas
activ
start
materi
anilin
react
chlorosulfonyl
isocyan
optim
reaction
condit
yield
subsequ
thionat
oxo
deriv
phosphoru
pentasulfid
pyridin
led
correspond
compound
next
step
compound
prepar
reaction
thioxo
compound
methyl
iodid
presenc
sodium
hydrogenocarbon
final
compound
treat
isopropyl
amin
optim
reaction
condit
obtain
final
product
scheme
compound
found
potent
glucoseinduc
insulin
secret
ri
valu
mm
per
mm
concentr
posit
chlorin
atom
benzen
ring
strongli
affect
activ
insulinsecret
cell
taken
whole
rank
order
potenc
compound
pancreat
bcell
found
taha
et
al
synthes
novel
imidazolepyridin
hybrid
screen
vitro
biolog
activ
compound
prepar
commerci
avail
start
materi
compound
react
substitut
aldehyd
presenc
na
dmf
solvent
reflux
condit
afford
desir
product
high
yield
scheme
newli
malaria
refer
parasit
infect
spread
worldwid
caus
seriou
problem
tropic
subtrop
part
asia
central
south
america
africa
middl
east
parasit
class
call
plasmodium
carri
femal
anophel
mosquito
caus
diseas
get
enter
human
bloodstream
treatment
manag
diseas
irrat
high
medic
also
due
low
product
complex
control
malaria
lie
grow
resist
malaria
parasit
antimalari
drug
use
seri
phthalazin
contain
imidazol
deriv
differ
substitut
pattern
synthes
evalu
vitro
antimalari
activ
extra
intracellular
form
cruzi
start
materi
treat
propylamin
presenc
k
co
reflux
condit
provid
compound
yield
scheme
compound
found
activ
vitro
extra
intracellular
form
cruzi
ic
valu
mm
epimastigot
form
less
toxic
vero
cell
better
standard
drug
benznidazol
furthermor
studi
antiparasit
activ
compound
higher
level
develop
new
drug
futur
synthes
compound
screen
use
rane
test
blood
schizonticid
activ
mice
infect
p
berghei
base
result
three
compound
possess
antimalari
activ
compar
chloroquin
compound
activ
one
librari
novel
triazin
substitut
hybrid
develop
kumar
et
al
evalu
vitro
antimalari
activ
p
falciparum
compound
stir
excess
nbutanol
optim
reaction
condit
give
ethanol
moder
good
yield
chemoselect
omesyl
synthes
pyridin
c
h
yield
themethanesulfon
acid
ethyl
ester
compound
subject
nucleophil
substitut
trisubstitut
triazin
yield
correspond
target
compound
microwav
condit
scheme
compound
display
suppress
activ
four
day
invitro
model
p
falciparum
show
high
suppress
chloroquin
resist
strain
p
yoelii
vivo
assay
new
seri
antimalari
activ
compound
develop
madrid
et
al
simpl
twostep
synthesi
method
use
prepar
ring
substitut
deriv
allow
analysi
effect
ring
substitut
inhibit
growth
chloroquin
sensit
resist
strain
p
falciparum
first
step
sequenc
condens
substitut
anilin
meldrum
acid
trimethylorthoform
give
eneamin
intermedi
seal
glass
reaction
tube
small
volum
phenyl
ether
solvent
subject
microwav
irradi
min
c
scheme
synthes
compound
evalu
growth
inhibit
activ
p
falciparum
help
fluorescentact
cell
sort
fac
assay
vitro
activ
two
strain
ie
drugsensit
drugresist
employ
form
studi
found
substitut
small
electron
withdraw
group
found
activ
antimalari
activ
alzheim
diseas
ad
neurodegen
disord
featur
cognit
dysfunct
memori
laps
account
major
dementia
case
accord
present
estim
million
peopl
go
diseas
worldwid
may
reach
million
condit
left
untreat
though
actual
etiolog
ad
progress
known
yet
number
pathophysiolog
factor
believ
respons
progress
diseas
deficit
acetylcholin
ach
inflamm
bamyloid
ab
deposit
oxid
stress
dyshomeostasi
biomet
tauprotein
aggreg
consid
pathophysiolog
factor
unfortun
medicin
cure
ad
progress
develop
yet
certain
medicin
approv
prescrib
ad
patient
temporari
relief
wang
et
al
synthes
new
seri
selenium
contain
hydrochlorid
deriv
test
vitro
multitarget
activ
alzheim
diseas
firstli
na
se
react
correspond
benzenediazonium
salt
prepar
commerci
avail
substitut
benzoic
acid
hno
yield
acid
subsequ
socl
react
reflux
condit
obtain
react
correspond
chloro
substitut
amin
anhydr
ch
cl
afford
final
target
compound
final
step
boc
group
remov
compound
use
hcl
ga
yield
deprotect
hydrochlorid
compound
scheme
compound
show
excel
alzheim
diseas
inhibit
activ
test
multitarget
enzym
mainli
compound
found
potent
ab
aggreg
agent
ic
valu
mm
virus
infecti
agent
affect
life
form
respons
variou
danger
diseas
like
human
immunodefici
viru
hiv
hepat
b
c
virus
hbv
hcv
respect
sever
acut
respiratori
syndrom
sar
corona
virus
middl
east
respiratori
syndrom
mer
influenza
season
pandem
viral
haemorrhag
fever
ebola
dengu
chikungunya
etc
diseas
caus
advers
impact
human
health
lead
unexpect
ill
death
troubl
daytoday
normal
life
activ
virus
major
caus
emerg
newer
pandem
eg
influenza
ebola
zika
viru
etc
threaten
public
health
likewis
antivir
drug
divers
chemic
class
approv
fda
mainli
treatment
hiv
hepat
b
c
herp
influenza
b
virus
still
mani
molecul
variou
stage
clinic
trial
still
press
need
develop
new
drug
act
sever
mechan
combat
viral
resist
virus
howev
alway
challeng
medicin
chemist
develop
newer
drug
focu
uniqu
biolog
featur
virus
treat
emerg
viral
diseas
one
way
without
harm
host
cell
regina
cowork
design
synthes
seri
novel
imidazol
deriv
simpl
singl
step
synthes
deriv
evalu
vitro
antihiv
activ
cell
initi
carboxyl
group
free
imidazol
react
variou
substitut
amin
presenc
bop
tea
dmf
room
temperatur
yield
compound
scheme
compound
exhibit
potent
antihiv
activ
cell
ic
valu
nm
compound
emerg
use
lead
compound
develop
new
therapeut
tool
efvbas
therapi
show
n
mutat
sar
reveal
presenc
pyridin
group
r
posit
highli
enhanc
activ
moreov
electronwithdraw
chloro
group
also
play
crucial
role
increas
antihiv
activ
boland
cowork
synthes
novel
seri
potent
candid
inhibitor
six
step
start
commerci
avail
difluoromethyl
dmso
use
sodium
chlorodifluoroacet
sourc
difluorocarben
provid
compound
alkyl
remain
hydroxyl
group
perform
alkyl
dibromid
yield
intermedi
next
step
aldehyd
compound
oxid
correspond
benzoic
acid
use
sodium
chlorit
lindgren
oxid
combin
sulfam
acid
chlorin
dioxid
scaveng
compound
coupl
provid
intermedi
compound
underw
nucleophil
substitut
afford
final
compound
scheme
final
synthes
compound
screen
inhibit
activ
two
compound
ic
nm
nm
ic
nm
nm
show
excel
inhibit
activ
compar
standard
drug
rolipram
ic
nm
nm
seri
novel
cannabinoid
type
receptor
antagonist
synthes
szabo
et
al
begin
cycloalkylbenzen
react
acylchlorid
trichloroethylen
optim
reaction
condit
provid
phenon
claisen
condens
acid
ethyl
ester
react
optim
reaction
condit
c
yield
diketon
ester
good
yield
synthesi
acid
involv
basic
hydrolysi
correspond
ester
turn
prepar
condens
diketon
ester
suitabl
substitut
phenyl
hydrazin
intermedi
convert
acid
chlorid
use
thionyl
chlorid
reflux
toluen
intermedi
react
commerci
avail
dichloromethan
room
temperatur
afford
compound
scheme
compound
found
potent
cannabinoid
type
receptor
antagonist
k
valu
nm
sar
studi
suggest
pyrazol
substitu
presenc
chloro
group
phenyl
ring
pyrrolidin
ring
enhanc
activ
novel
antagonist
lan
evalu
seri
deriv
current
underway
laboratori
report
due
cours
cao
cowork
design
synthes
new
seri
pyridazinon
substitut
analogu
evalu
vitro
antineuropath
pain
activ
start
materi
phenylhydrazin
hydrochlorid
react
maleic
anhydrid
presenc
conc
hcl
reflux
condit
obtain
cycliz
product
compound
alkyl
yield
react
piperidin
afford
final
compound
moder
yield
scheme
compound
show
potent
receptor
affin
k
nm
excel
select
receptor
profil
suggest
compound
may
novel
class
candid
drug
treatment
neuropath
pain
nencka
cowork
develop
seri
novel
analogu
potent
inhibitori
agent
recombin
human
tp
express
chines
hamster
cell
commerci
avail
underw
direct
ortholithi
butyllithium
c
afford
intermedi
compound
compound
react
aceton
c
temperatur
reach
room
temperatur
afford
final
step
compound
treat
con
hcl
dioxan
reflux
condit
obtain
target
compound
good
yield
scheme
effect
inhibitor
compound
inhibit
enzym
express
cell
competit
k
mm
enzym
purifi
placenta
ki
mm
manner
studi
chang
tradit
view
uracilbas
tp
inhibitor
provid
novel
lead
research
recent
tzvetkov
cowork
report
indol
substitut
analogu
potent
monoamin
oxidas
b
inhibitor
target
compound
synthes
singl
step
commerci
avail
indol
carboxyl
acid
compound
coupl
dichloro
amin
use
coupl
reagent
edchcl
methanol
room
temperatur
give
compound
good
yield
scheme
compound
screen
scheme
synthet
rout
pyrrolidin
contain
hybrid
potent
cannabinoid
type
receptor
antagonist
reagent
condit
r
ch
cocl
alcl
trichloroethylen
c
ii
lihmd
thf
acid
ethyl
ester
c
n
hcl
iii
hydrochlorid
etoh
reflux
iv
n
koh
meoh
reflux
v
cocl
dmf
ch
cl
rt
vi
ch
cl
rt
scheme
synthet
rout
aminoalkoxi
pyrimidin
deriv
potent
neuropath
pain
agent
reagent
condit
tbuok
meoh
reflux
ii
br
ch
br
k
co
aceton
reflux
iii
piperidin
cs
co
acetonitril
reflux
monoamin
oxidas
b
inhibit
activ
show
potent
activ
ic
valu
nm
human
maob
nm
human
maoa
enzym
futur
effort
direct
toward
improv
compound
druglik
properti
regard
watersolubl
bioavail
metabol
toxic
evalu
new
maob
inhibitor
relev
anim
model
recent
kadayat
cowork
develop
pyridin
potent
topoisomeras
inhibitor
first
step
condens
aryl
aldehyd
prepar
indanon
intermedi
presenc
aqueou
naoh
ethanol
use
claisenschmidt
condens
reaction
six
pyridinium
iodid
salt
synthes
reflux
acetophenon
iodin
pyridin
final
use
modifi
ohnk
synthesi
indanon
intermedi
pyridinium
iodid
salt
react
presenc
dri
ammonium
acet
methanol
acet
acid
yield
compound
moder
yield
scheme
synthes
eighteen
new
chlorin
compound
assess
topoisomeras
inhibitori
activ
cytotox
hela
cancer
cell
line
among
compound
ic
nm
ic
nm
cell
line
ic
nm
ic
nm
cell
line
show
potent
topoisomeras
activ
better
refer
drug
chlorin
compound
display
signific
cytotox
effect
reveal
potent
anticanc
activ
breast
cancer
cell
synthesi
new
class
acaricid
insecticid
agent
carri
kadayat
cowork
synthet
rout
medium
length
includ
three
chemic
step
first
step
react
substitut
phenol
presenc
koh
optim
reaction
condit
obtain
intermedi
compound
compound
react
hydroxylamin
hydrochlorid
methanol
ethanol
medium
yield
compound
pyrazol
oxim
good
yield
treatment
intermedi
acetonitril
medium
use
potassium
carbon
alkali
produc
correspond
pyrazol
oxim
contain
substitut
moieti
scheme
newli
synthes
compound
evalu
vitro
acaricid
insecticid
activ
compound
show
potent
insecticid
activ
p
xylostella
lc
valu
mm
better
control
compound
pyridalyl
lc
mm
recent
taha
cowork
develop
novel
class
indol
deriv
potent
aamylas
inhibit
agent
synthet
rout
simpl
includ
two
step
first
step
indol
ethyl
ester
convert
indolehydrazid
use
hydrazin
hydrat
ethanol
reflux
condit
h
indol
hydrazid
react
variou
aromat
isothiocyan
chloroform
stir
h
yield
final
target
indol
deriv
product
good
yield
scheme
synthes
compound
test
aamylas
inhibitori
activ
compound
display
potent
aamylas
inhibitori
activ
ic
valu
mm
mm
respect
sar
reveal
presenc
electron
withdraw
group
cl
f
phenyl
ring
highli
enhanc
aamylas
activ
compound
substitu
paraposit
activ
ortho
meta
counterpart
chourey
cowork
design
synthes
novel
eicosatetraeno
acid
potent
oxe
receptor
agent
chloro
substitut
indol
analog
react
r
methyl
optim
reaction
condit
obtain
intermedi
good
yield
methyl
ester
group
intermedi
convert
free
carboxyl
acid
group
use
lioh
h
thfh
room
temperatur
obtain
final
compound
good
yield
scheme
synthes
compound
found
potent
oxe
receptor
ic
valu
pm
new
highli
potent
oxer
antagonist
may
provid
novel
strategi
treatment
eosinophil
disord
like
asthma
sar
reveal
addit
phenyl
group
end
hexyl
side
chain
oxer
antagonist
contribut
dramat
increas
vitro
potenc
halflif
circulatori
system
administ
oral
monkey
kumar
et
al
design
synthes
novel
seri
quinolinyl
amin
screen
vitro
antidepress
activ
intermedi
product
chloromethyl
prepar
two
step
via
reduct
nabh
follow
chlorin
socl
quinolinyl
amin
prepar
nucleophil
substitut
reaction
variou
amin
absolut
ethanol
presenc
base
triethylamin
scheme
compound
show
promis
antidepress
activ
preliminari
sar
quinolinyl
amin
suggest
compound
electron
scheme
synthesi
thiadiazol
contain
pyrazol
oxim
deriv
potent
acaricid
insecticid
agent
reagent
condit
substitut
phenol
koh
dmf
dmso
c
h
c
h
ii
nh
ohhcl
koh
ch
oh
ch
ch
oh
reflux
h
iii
substitut
k
co
ch
withdraw
group
f
cl
show
good
antidepress
activ
bouloc
cowork
develop
pyrazin
substitut
hybrid
test
vitro
aurora
kinas
inhibitori
activ
start
materi
pyrazin
chlorin
posit
presenc
nc
optim
reaction
condit
afford
intermedi
compound
intermedi
underw
aromat
nucleophil
substitut
posit
provid
compound
follow
chemoselect
suzuki
crosscoupl
posit
afford
final
compound
scheme
compound
found
potent
aurora
inhibitori
agent
ic
mm
karthik
cowork
develop
chitosan
silver
nanoparticl
cagnp
potent
antihemolyt
agent
start
materi
pchloro
isocyan
react
base
tea
dichloromethan
room
temperatur
obtain
compound
n
b
good
yield
scheme
final
compound
convert
silver
nanoparticl
cagnp
final
silver
coat
nanoparticl
evalu
vitro
antiinflammatori
activ
compound
show
potent
antihemolyt
activ
ic
valu
mgml
compound
also
show
potent
phospholipas
enzym
inhibitori
activ
ic
valu
mgml
much
better
refer
drug
diclofenac
mgml
recent
jalaja
et
al
prepar
triazol
deriv
natur
product
potent
pancreat
lipas
inhibitor
start
materi
propargyl
labdan
react
variou
substitut
benzyl
phenacyl
azid
room
temperatur
provid
append
labdan
deriv
good
excel
yield
scheme
synthes
natur
product
deriv
labdan
append
triazol
evalu
pancreat
lipas
inhibitor
activ
among
compound
found
potent
pancreat
lipas
inhibitor
agent
ic
valu
mm
much
better
refer
drug
orlistat
ic
mm
hangeland
cowork
synthes
potent
lipas
inhibitor
start
materi
ethyl
compound
first
omethyl
trimethylsilyldiazomethan
presenc
dipea
follow
saponif
ester
free
carboxyl
acid
coupl
amin
use
correspond
acid
chlorid
gener
oxalyl
chlorid
result
amid
demethyl
boron
trichlorid
yield
final
product
moder
yield
scheme
produc
analogu
screen
small
set
nonselect
lipas
inhibitor
endotheli
lipas
el
identifi
potent
revers
inhibitor
compound
el
sub
hdl
sub
ic
nm
show
good
inhibitori
activ
test
endotheli
lipas
novel
class
pyridopyrimidinon
deriv
synthes
yu
et
al
evalu
enzym
activ
mtor
addit
reaction
nc
optim
reaction
condit
provid
intermedi
subsequ
chlorinesubstitut
react
pyridineboron
acid
pinacol
ester
afford
final
product
scheme
compound
evalu
novel
class
efficaci
dual
inhibitor
compound
show
good
enzym
activ
mtor
ic
nm
potent
suppress
akt
phosphoryl
cellular
assay
furthermor
compound
also
demonstr
signific
vivo
efficaci
tumour
xenograft
model
novel
class
sulfonamid
deriv
synthes
kindon
et
al
evalu
receptor
antagonist
synthes
target
compound
lengthi
includ
six
chemic
step
start
commerci
avail
dibor
select
displac
bromin
sodium
methoxid
obtain
bromin
remov
hydrogen
coupl
chlorid
yield
highli
select
nitrat
follow
reduct
nitro
group
gave
aminopyrazin
diazot
presenc
hydrofluor
acid
give
good
yield
scheme
synthes
final
compound
intermedi
screen
receptor
inhibit
activ
compound
pic
pic
show
good
potenc
human
receptor
last
recent
filipski
cowork
develop
potent
sodiumphosph
cotransport
inhibitor
pyrrol
deriv
react
enol
tosyl
form
dbu
use
effect
pyridin
ring
cycliz
give
azaindol
convers
correspond
accomplish
use
phosphoru
oxychlorid
nchlorosuccinimid
chlorin
yield
sub
n
sub
ar
provid
desir
scheme
compound
screen
sodiumphosph
cotransport
inhibitor
activ
compound
ic
nm
found
good
inhibitor
compound
first
oral
bioavail
select
inhibitor
repres
pharmacolog
tool
probe
function
effect
select
inhibit
vivo
chlorin
base
drug
medicin
chemistri
attract
use
studi
exact
frequenc
drug
target
distribut
divers
biolog
applic
way
us
fda
approv
pharmaceut
addit
hope
synthet
organ
chemistri
research
could
improv
way
synthes
potent
chlorinebas
drug
well
underrepres
nonexist
drug
review
mainli
focus
synthesi
chlorin
drug
chlorin
drug
function
approv
date
diseas
condit
chlorin
attach
structureact
relationship
believ
review
articl
use
inspir
structur
design
develop
less
toxic
power
chlorinebas
drug
numer
deathcaus
diseas
